Search

Your search keyword '"Smith, CATHERINE H."' showing total 573 results
Start Over Author "Smith, CATHERINE H."
573 results on '"Smith, CATHERINE H."'

2. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Author

Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla GS, Griffiths, Christopher EM, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Rodriguez, Deshire Alpizar, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Martins, Frederico Rajão, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, de los Ángeles Severina, María, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas ZN, Yazdany, Jinoos, Robinson, Philip C, and Smith, Catherine H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Lung, Infectious Diseases, Coronaviruses, Arthritis, Clinical Research, Psoriasis, Emerging Infectious Diseases, 6.1 Pharmaceuticals, Inflammatory and immune system, Good Health and Well Being, Adult, Humans, Male, Arthritis, Psoriatic, Rheumatology, COVID-19, Axial Spondyloarthritis, Physicians, Glucocorticoids, Interleukin-12, Registries, Covid-19, Psoriatic, Autoimmunity, Spondylitis, Ankylosing, Spondylitis, Ankylosing, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).MethodsDemographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression.ResultsOf 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19.ConclusionOlder age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.

Published
2023

3. A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis

Author

Abraham, Thamir, Ali, Muhmad, August, Suzannah, Baudry, David, Becher, Gabrielle, Bewley, Anthony, Brown, Victoria, Cornelius, Victoria, Ghaffar, Sharizan, Ingram, John, Kavakleiva, Svetlana, Kelly, Susan, Khorshid, Mohsen, Lachmann, Helen, Ladoyanni, Effie, McAteer, Helen, McKenna, John, Meynell, Freya, Patel, Prakash, Pink, Andrew, Powell, Kingsley, Pushparajah, Angela, Sinclair, Catriona, Wachsmuth, Rachel, Hernandez-Cordero, Ariana, Thomas, Laurent, Smail, Alice, Lim, Zhao Qin, Saklatvala, Jake R., Chung, Raymond, Curtis, Charles J., Baum, Patrick, Visvanathan, Sudha, Burden, A. David, Cooper, Hywel L., Dunnill, Giles, Griffiths, Christopher E.M., Levell, Nick J., Parslew, Richard, Reynolds, Nick J., Wahie, Shyamal, Warren, Richard B., Wright, Andrew, Simpson, Michael, Hveem, Kristian, Barker, Jonathan N., Dand, Nick, Løset, Mari, Smith, Catherine H., and Capon, Francesca

Published
2024
Full Text
View/download PDF

7. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics

Author

Ahmed, Shehnaz, Alabas, Oras, Barker, Jonathan, Becher, Gabrielle, Bewley, Anthony, Evans, Ian, Hampton, Philip, Kirby, Brian, Kleyn, Elise, Laws, Philip, Lawson, Linda, Mackenzie, Teena, McElhone, Kathleen, McPherson, Tess, Morrison, Simon, Owen, Caroline, Pearson, Eleanor, Rashid, Amir, Reynolds, Nick, Strangfeld, Anja, Walton, Shernaz, Yiu, Zenas, Gupta, Girish, Strangfeld (chair), Anja, Weller, Richard, Zietemann, Vera, Aldoori, Nadia, Ali, Mahmud, Al-Rusan, Ahmed, Angit, Caroline, Anstey, Alex, Antony, Fiona, Archer, Charles, August, Suzanna, Balasubramaniam, Periasamy, Baudry, David, Baxter, Kay, Bonsall, Alexandra, Brown, Sara, Brown, Victoria, Burden, David, Burova, Ekaterina, Butt, Aamir, Caswell, Mel, Chapman, Anna, Cliff, Sandeep, Costache, Mihaela, Darne, Sharmela, DeGiovanni, Claudia, Desai, Trupti, Diba, Victoria, Domanne, Eva, Duckworth, Michael, Dymond, Harvey, Fahy, Caoimhe, Farwer, Susanne, Ferguson, Leila, Gkini, Maria-Angeliki, Godwin, Alison, Goulding, Jon, Hammonds, Fiona, Haque, Shaheen, Higgins, Caroline, Hood, Sue, Joseph, Teresa, Johnson, Sarah, Kalavala, Manju, Khorshid, Mohsen, Labinoti, Liberta, Lamb, Ruth, Lawson, Nicole, Layton, Alison, Lees, Tara, Levell, Nick, Lewis, Helen, Lovell, Chris, Lyon, Calum, McAteer, Helen, McBride, Sandy, McCormack, Sally, McKenna, Kevin, Mellor, Serap, Meredith, Fiona, Murphy, Ruth, Norris, Paul, Parslew, Richard, Perera, Gay, Ponnambath, Nabil, Popli, Urvi, Powell, James, Ramesh, Raakhee, Ramsay, Helen, Ranasinghe, Aruni, Reeken, Saskia, Rose, Rebecca, Rotarescu, Rada, Salvary, Ingrid, Sands, Kathy, Sinha, Tapati, Schofield, Julia, Shipman, Alexa, Siebert, Stefan, Stefanescu, Simina, Sundararaj, Kavitha, Taghipour, Kathy, Taylor, Michelle, Thomson, Michelle, Topliffe, Joanne, Verdolini, Roberto, Wachsmuth, Rachel, Wade, Martin, Wahie, Shymal, Walsh, Sarah, Wilcox, Louise, Williamson, Diane, Wright, Andrew, Al-Janabi, Ali, Martin, Paul, Khan, Adnan R., Foulkes, Amy C., Smith, Catherine H., Griffiths, Christopher E.M., Morris, Andrew P., Eyre, Steve, and Warren, Richard B.

Published
2023
Full Text
View/download PDF

11. Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis

Author

McCluskey, Daniel, Benzian-Olsson, Natashia, Mahil, Satveer K., Hassi, Niina Karoliina, Wohnhaas, Christian T., Burden, A. David, Griffiths, Christopher E.M., Ingram, John R., Levell, Nick J., Parslew, Richard, Pink, Andrew E., Reynolds, Nick J., Warren, Richard B., Visvanathan, Sudha, Baum, Patrick, Barker, Jonathan N., Smith, Catherine H., and Capon, Francesca

Published
2022
Full Text
View/download PDF

13. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

Author

MacKenna, Brian, Kennedy, Nicholas A, Mehrkar, Amir, Rowan, Anna, Galloway, James, Matthewman, Julian, Mansfield, Kathryn E, Bechman, Katie, Yates, Mark, Brown, Jeremy, Schultze, Anna, Norton, Sam, Walker, Alex J, Morton, Caroline E, Harrison, David, Bhaskaran, Krishnan, Rentsch, Christopher T, Williamson, Elizabeth, Croker, Richard, Bacon, Seb, Hickman, George, Ward, Tom, Davy, Simon, Green, Amelia, Fisher, Louis, Hulme, William, Bates, Chris, Curtis, Helen J, Tazare, John, Eggo, Rosalind M, Evans, David, Inglesby, Peter, Cockburn, Jonathan, McDonald, Helen I, Tomlinson, Laurie A, Mathur, Rohini, Wong, Angel Y S, Forbes, Harriet, Parry, John, Hester, Frank, Harper, Sam, Douglas, Ian J, Smeeth, Liam, Lees, Charlie W, Evans, Stephen J W, Goldacre, Ben, Smith, Catherine H, and Langan, Sinéad M

Published
2022
Full Text
View/download PDF

14. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis

Author

Evans, Ian, Murphy, Ruth, McPherson, Tess, Kleyn, Elise, Laws, Philip, Becher, Gabrielle, Bewley, Anthony, Rashid, Amir, Alabas, Oras, Morrison, Simon, Ahmed, Shehnaz, Pearson, Eleanor, Richards, Josh, Mackenzie, Teena, Kirby, Brian, Burden, David, Lawson, Linda, McElhone, Kathleen, Ormerod, Anthony, Owen, Caroline, Aldoori, Nadia, Ali, Mahmud, Anstey, Alex, Antony, Fiona, Archer, Charles, August, Suzanna, Balasubramaniam, Periasamy, Baxter, Kay, Bonsall, Alexandra, Brown, Victoria, Burova, Katya, Butt, Aamir, Caswell, Mel, Cliff, Sandeep, Costache, Mihaela, Darne, Sharmela, Davies, Emily, DeGiovanni, Claudia, Desai, Trupti, DeSilva, Bernadette, Diba, Victoria, Domanne, Eva, Dymond, Harvey, Fahy, Caoimhe, Ferguson, Leila, Gkini, Maria-Angeliki, Godwin, Alison, Hammonds, Fiona, Johnson, Sarah, Joseph, Teresa, Kalavala, Manju, Khorshid, Mohsen, Labinoti, Liberta, Lawson, Nicole, Layton, Alison, Lees, Tara, Levell, Nick, Lewis, Helen, Lyon, Calum, McBride, Sandy, McCormack, Sally, McKenna, Kevin, Mellor, Serap, Norris, Paul, Popli, Urvi, Perera, Gay, Ponnambath, Nabil, Ramsay, Helen, Ranasinghe, Aruni, Reeken, Saskia, Rose, Rebecca, Rotarescu, Rada, Salvary, Ingrid, Sands, Kathy, Sinha, Tapati, Stefanescu, Simina, Sundararaj, Kavitha, Taghipour, Kathy, Taylor, Michelle, Thomson, Michelle, Topliffe, Joanne, Verdolini, Roberto, Wachsmuth, Rachel, Wade, Martin, Wahie, Shyamal, Walsh, Sarah, Walton, Shernaz, Wilcox, Louise, Wright, Andrew, Douroudis, Konstantinos, Ramessur, Ravi, Barbosa, Ines A., Baudry, David, Duckworth, Michael, Angit, Caroline, Capon, Francesca, Chung, Raymond, Curtis, Charles J., Di Meglio, Paola, Goulding, Jonathan M.R., Griffiths, Christopher E.M., Lee, Sang Hyuck, Mahil, Satveer K., Parslew, Richard, Reynolds, Nick J., Shipman, Alexa R., Warren, Richard B., Yiu, Zenas Z.N., Simpson, Michael A., Barker, Jonathan N., Dand, Nick, and Smith, Catherine H.

Published
2022
Full Text
View/download PDF

17. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

Author

Mahil, Satveer K, Bechman, Katie, Raharja, Antony, Domingo-Vila, Clara, Baudry, David, Brown, Matthew A, Cope, Andrew P, Dasandi, Tejus, Graham, Carl, Khan, Hataf, Lechmere, Thomas, Malim, Michael H, Meynell, Freya, Pollock, Emily, Sychowska, Kamila, Barker, Jonathan N, Norton, Sam, Galloway, James B, Doores, Katie J, Tree, Timothy, and Smith, Catherine H

Published
2022
Full Text
View/download PDF

18. Genome-wide association meta-analysis identifies 29 new acne susceptibility loci

Author

Mitchell, Brittany L., Saklatvala, Jake R., Dand, Nick, Hagenbeek, Fiona A., Li, Xin, Min, Josine L., Thomas, Laurent, Bartels, Meike, Jan Hottenga, Jouke, Lupton, Michelle K., Boomsma, Dorret I., Dong, Xianjun, Hveem, Kristian, Løset, Mari, Martin, Nicholas G., Barker, Jonathan N., Han, Jiali, Smith, Catherine H., Rentería, Miguel E., and Simpson, Michael A.

Published
2022
Full Text
View/download PDF

19. A genome-wide meta-analysis of palmoplantar pustulosis implicates Th2 responses and cigarette smoking in disease pathogenesis.

Author

Hernandez-Cordero, Ariana, primary, Thomas, Laurent, additional, Smail, Alice, additional, Lim, Zhao Qin, additional, Saklatvala, Jake R., additional, Chung, Raymond, additional, Curtis, Charles J., additional, Baum, Patrick, additional, Visvanathan, Sudha, additional, Burden, A David, additional, Cooper, Hywel L., additional, Dunnill, Giles, additional, Griffiths, Christopher EM., additional, Levell, Nick J., additional, Parslew, Richard, additional, Reynolds, Nick J., additional, Wahie, Shyamal, additional, Warren, Richard B., additional, Wright, Andrew, additional, Simpson, Michael, additional, Hveem, Kristian, additional, Barker, Jonathan N., additional, Dand, Nick, additional, Loset, Mari, additional, Smith, Catherine H., additional, and Capon, Francesca, additional

Published
2024
Full Text
View/download PDF

21. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Author

Mahil, Satveer K, Bechman, Katie, Raharja, Antony, Domingo-Vila, Clara, Baudry, David, Brown, Matthew A, Cope, Andrew P, Dasandi, Tejus, Graham, Carl, Lechmere, Thomas, Malim, Michael H, Meynell, Freya, Pollock, Emily, Seow, Jeffery, Sychowska, Kamila, Barker, Jonathan N, Norton, Sam, Galloway, James B, Doores, Katie J, Tree, Timothy I M, and Smith, Catherine H

Published
2021
Full Text
View/download PDF

24. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Author

Shah, Aadarsh, Barea, Alberto, Romero-Maté, Alberto, Singapore, Alekya, Paolino, Alexandra, Mwale, Alice, Morales Callaghan, Ana Maria, Martinez, Ana, DeCrescenzo, Andrew, Pink, Andrew E., Jones, Ann, Sergeant, Ann, Essex, Annette, Bewley, Anthony, Makrygeorgou, Areti, van Huizen, Astrid, Pérez-Suárez, Beatriz, Farida, Benhadou, Claréus, Birgitta Wilson, Prims, Carla Tubau, Davis, Carrie, Quinlan, Catherine, Maybury, Catriona, Cesar, Gonzalez A., Barclay, Charlotte, Greco, Claudio, Brassard, Danielle, Cummings, Deanna, Kolli, Deepti, Descamps, Vincent, Genao, Diana Ruiz, Carras, Efrossini, Hawryluk, Elena, Martínez-García, Eliseo, Klujszo, Elzbieta, Dwyer, Emily, Toni, Emmanuel, Sonkoly, Enikö, Loayza, Enrique, Daudén, Esteban, Valenzuela, Fernando, Popov, Georgi, King, Georgie, Celine, Girard, Aparicio, Gloria, Johnston, Graham A., Cardozo, Gustavo Anibal, Pearson, Ian, Yanguas, Ignacio, Weisman, Jamie, Carolan, Jennifer E., Hughes, Jenny, Ortiz-Salvador, Jose-Maria, Carrascosa, Jose-Manuel, Schwartz, Joseph J., Jackson, Karina, Kerisit, Kathryn G., Wu, Keith, Asfour, Leila, de Graaf, Leontien, Lesort, Cécile, Meuleman, Lieve, Eidsmo, Liv, Skov, Lone, Gribben, Lorraine, Rustin, Malcolm, Velasco, Manel, Panchal, Manisha, Lakhan, Manpreet, Franco, Manuel D., Svensson, Marie-Louise, Vandaele, Mark, Marovt, Maruska, Zargari, Omid, De Caso, Pablo, Varela, Paulo, Jenkin, Peter, Phan, Céline, Hampton, Philip, Goldsmith, Portia, Bak, Rachel, Speeckaert, Reinhart, Romiti, Ricardo, Woolf, Richard, Mercado-Seda, Rogelio, Khatun, Rohima, Ceovic, Romana, Taberner, Rosa, Cohen, Russell W., Stefanescu, Simina, Kirk, Sarah, Reeken, Saskia, Ayob, Shanti, Pérez-Barrio, Silvia, Piaserico, Stefano, Hoey, Susannah, Torres, Tiago, Talme, Toomas, Desai, Trupti V., van Geest, Adrienne J., King, Victoria, Di Lernia, Vito, Koreja, Zahira, Hasab, Vito Zeeshaan, Mahil, Satveer K., Dand, Nick, Mason, Kayleigh J., Yiu, Zenas Z.N., Tsakok, Teresa, Meynell, Freya, Coker, Bola, McAteer, Helen, Moorhead, Lucy, Mackenzie, Teena, Rossi, Maria Teresa, Rivera, Raquel, Mahe, Emmanuel, Carugno, Andrea, Magnano, Michela, Rech, Giulia, Balogh, Esther A., Feldman, Steven R., De La Cruz, Claudia, Choon, Siew Eng, Naldi, Luigi, Lambert, Jo, Spuls, Phyllis, Jullien, Denis, Bachelez, Hervé, McMahon, Devon E., Freeman, Esther E., Gisondi, Paolo, Puig, Luis, Warren, Richard B., Di Meglio, Paola, Langan, Sinéad M., Capon, Francesca, Griffiths, Christopher E.M., Barker, Jonathan N., and Smith, Catherine H.

Published
2021
Full Text
View/download PDF

25. Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study.

Author

Gleeson, David, Naveed, Maneeha, Moorhead, Lucy, McAteer, Helen, Sewell, Georgia, McGuire, Arlene, Weinman, John, Barker, Jonathan N W N, Norton, Sam, Chapman, Sarah C E, Smith, Catherine H, and Mahil, Satveer K

Subjects
BIOTHERAPY, PSORIASIS, PATIENTS' attitudes, PATIENT preferences, PATIENT selection, DERMATOLOGISTS
Abstract

Background Biologic therapies have led to increasing numbers of patients with psoriasis who have clear or nearly clear skin. It is current practice to continue biologic therapy indefinitely in these patients, which contributes to a substantial long-term drug and healthcare burden. 'As needed' biologic therapy in psoriasis may address this; however, our understanding of patient and clinician perceptions of this strategy is limited. Objectives The aim of this mixed-methods study was to gain insight into the perspectives of both patients and clinicians regarding the acceptability of an 'as needed' approach to biologic therapy in psoriasis, including potential barriers and enablers to implementation in routine care. Methods We first conducted UK-wide online scoping surveys of patients with psoriasis and dermatology clinicians to explore their views on 'as needed' biologic therapy. Using topic guides informed by these survey findings, we then carried out qualitative focus groups with patients and clinicians. Themes were identified using reflexive thematic analysis. Results Of 67 patients and 27 clinicians completing the scoping surveys, 67% (43 of 64 patients) and 78% (21 of 27 clinicians) supported the use of 'as needed' biologic therapy, respectively. Respondents highlighted advantages such as a reduction in healthcare burden and greater ownership of care. Challenges included logistics of 'as needed' drug provision and potential risks of disease flare and drug immunogenicity. Focus groups comprised 15 patients with psoriasis [9 female patients (60%), average disease duration 32 years (range 9–64)] and 9 dermatology clinicians [8 female clinicians (89%), average dermatology experience 20 years (range 8–33)]. Both patients and clinicians felt that an 'as needed' treatment approach will deliver a reduction in treatment burden and present an opportunity for patient-led ownership of care. Both groups highlighted the importance of ensuring ongoing access to medication and discussing the potential impact of psoriasis recurrence. Patient preferences were influenced by their lived experiences, particularly previous difficulties with medication delivery logistics and establishing disease control. Clinician perspectives were informed by personal experience of their patients adapting their own dosing schedules. Clinicians highlighted the importance of targeted patient selection for an 'as needed' approach, ongoing disease monitoring, and prompt reaccess to medications upon psoriasis recurrence. Conclusions These data indicate that 'as needed' biologic therapy in psoriasis is acceptable for both patients and clinicians. Formal assessment of clinical effectiveness and cost-effectiveness is warranted to enable the real-world potential of this approach to be realized. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study

Author

Barker, Jonathan, Benham, Marilyn, Burden, David, Evans, Ian, Griffiths, Christopher, Hussain, Sagair, Kirby, Brian, Lawson, Linda, Mason, Kayleigh, McElhone, Kathleen, Murphy, Ruth, Ormerod, Anthony, Owen, Caroline, Reynolds, Nick, Smith, Catherine, Warren, Richard, Barker, Jonathan N.W.N., Barnes, Michael R., Burden, A. David, DiMeglio, Paola, Emsley, Richard, Evans, Andrea, Griffiths, Christopher E.M., Payne, Katherine, Reynolds, Nick J., Smith, Catherine H., Stocken, Deborah, Warren, Richard B., Loeff, Floris C., Tsakok, Teresa, Dijk, Lisanne, Hart, Margreet H., Duckworth, Michael, Baudry, David, Russell, Alice, Dand, Nick, van Leeuwen, Astrid, de Vries, Annick, Bloem, Karien, Wolbink, Gerrit Jan, and Rispens, Theo

Published
2020
Full Text
View/download PDF

29. Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an interdisciplinary perspective

Author

Ramessur, Ravi, primary, Dand, Nick, additional, Langan, Sinéad M, additional, Saklatvala, Jake, additional, Fritzsche, Marie-Christine, additional, Holland, Suzi, additional, Arents, Bernd W M, additional, McAteer, Helen, additional, Proctor, Andrew, additional, McMahon, David, additional, Greenwood, Michelle, additional, Buyx, Alena M, additional, Messer, Tamara, additional, Weiler, Nina, additional, Hicks, Alexandra, additional, Hecht, Peter, additional, Weidinger, Stephan, additional, Ndlovu, Matladi N, additional, Chengliang, Dai, additional, Hübenthal, Matthias, additional, Egeberg, Alexander, additional, Paternoster, Lavinia, additional, Skov, Lone, additional, De Jong, Elke M G J, additional, Middelkamp-Hup, Maritza A, additional, Mahil, Satveer K, additional, Barker, Jonathan N, additional, Flohr, Carsten, additional, Brown, Sara J, additional, and Smith, Catherine H, additional

Published
2024
Full Text
View/download PDF

31. Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models

Author

Jalali-najafabadi, Farideh, Stadler, Michael, Dand, Nick, Jadon, Deepak, Soomro, Mehreen, Ho, Pauline, Marzo-Ortega, Helen, Helliwell, Philip, Korendowych, Eleanor, Simpson, Michael A., Packham, Jonathan, Smith, Catherine H., Barker, Jonathan N., McHugh, Neil, Warren, Richard B., Barton, Anne, and Bowes, John

Published
2021
Full Text
View/download PDF

32. Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis

Author

Andres-Ejarque, Rosa, Ale, Hira Bahadur, Grys, Katarzyna, Tosi, Isabella, Solanky, Shane, Ainali, Chrysanthi, Catak, Zeynep, Sreeneebus, Hemawtee, Saklatvala, Jake, Dand, Nick, de Rinaldis, Emanuele, Chapman, Anna, Nestle, Frank O., Barnes, Michael R., Warren, Richard B., Reynolds, Nick J., Griffiths, Christopher E. M., Barker, Jonathan N., Smith, Catherine H., and Di Meglio, Paola

Published
2021
Full Text
View/download PDF

33. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis

Author

Andres-Ejarque, Rosa, Ale, Hira Bahadur, Grys, Katarzyna, Tosi, Isabella, Solanky, Shane, Ainali, Chrysanthi, Catak, Zeynep, Sreeneebus, Hemawtee, Saklatvala, Jake, Dand, Nick, de Rinaldis, Emanuele, Chapman, Anna, Nestle, Frank O., Barnes, Michael R., Warren, Richard B., Reynolds, Nick J., Griffiths, Christopher E. M., Barker, Jonathan N., Smith, Catherine H., and Di Meglio, Paola

Published
2021
Full Text
View/download PDF

34. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis

Author

Benham, Marilyn, Hussain, Sagair, Kirby, Brian, Lawson, Linda, McElhone, Kathleen, Ormerod, Anthony, Owen, Caroline, Barnes, Michael R., Di Meglio, Paola, Emsley, Richard, Evans, Andrea, Payne, Katherine, Stocken, Deborah, Dand, Nick, Duckworth, Michael, Baudry, David, Russell, Alice, Curtis, Charles J., Lee, Sang Hyuck, Evans, Ian, Mason, Kayleigh J., Alsharqi, Ali, Becher, Gabrielle, Burden, A. David, Goodwin, Richard G., McKenna, Kevin, Murphy, Ruth, Perera, Gayathri K., Rotarescu, Radu, Wahie, Shyamal, Wright, Andrew, Reynolds, Nick J., Warren, Richard B., Griffiths, Christopher E.M., Smith, Catherine H., Simpson, Michael A., and Barker, Jonathan N.

Published
2019
Full Text
View/download PDF

35. Clinical and genetic differences between pustular psoriasis subtypes

Author

Twelves, Sophie, Mostafa, Alshimaa, Dand, Nick, Burri, Elias, Farkas, Katalin, Wilson, Rosemary, Cooper, Hywel L., Irvine, Alan D., Oon, Hazel H., Kingo, Külli, Köks, Sulev, Mrowietz, Ulrich, Puig, Luis, Reynolds, Nick, Tan, Eugene Sern-Ting, Tanew, Adrian, Torz, Kaspar, Trattner, Hannes, Valentine, Mark, Wahie, Shyamal, Warren, Richard B., Wright, Andrew, Bata-Csörgő, Zsuzsa, Szell, Marta, Griffiths, Christopher E.M., Burden, A. David, Choon, Siew-Eng, Smith, Catherine H., Barker, Jonathan N., Navarini, Alexander A., and Capon, Francesca

Published
2019
Full Text
View/download PDF

36. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Author

Alabas, Oras A, Mason, Kayleigh J, Yiu, Zenas Z N, Warren, Richard B, Dand, Nick, Barker, Jonathan N, Smith, Catherine H, Griffiths, Christopher E M, and group, the BADBIR and BSTOP study

Subjects
AGE of onset, OVERALL survival, IMMUNOMODULATORS, PSORIASIS, DERMATOLOGISTS
Abstract

Background Few studies have used real-world data to investigate the association between biologic therapy survival and age at psoriasis onset or HLA-C*06:02 status in patients with moderate-to-severe psoriasis. The robustness of these studies is limited by small sample size, short follow-up and diverse safety and effectiveness measures. Objectives To describe biologic survival and explore whether the response to biologics is modified by age at psoriasis onset or HLA-C*06:02 status in patients with moderate-to-severe psoriasis. Methods Data from patients in the UK and the Republic of Ireland registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from 2007 to 2022 on a first course of adalimumab, etanercept, secukinumab or ustekinumab with at least 6 months' follow-up and a subset of BADBIR patients with available HLA-C*06:02 information registered to Biomarkers and Stratification To Optimise outcomes in Psoriasis (BSTOP) were analysed. Patients aged ≥ 50 years at treatment initiation were classified into early-onset psoriasis (EOP) (presenting in patients ≤ 40 years of age) and late-onset psoriasis (LOP) (presenting in patients > 40 years of age). BADBIR patients with available information in BSTOP were categorized as HLA-C*06:02− or HLA-C*06:02 +. Biologic survival was defined as treatment discontinuation associated with ineffectiveness or occurrence of adverse events (AEs). Adjusted survival function and hazard ratio (aHR) with 95% confidence interval (CI) were estimated using a flexible parametric model to compare discontinuing therapy between age at psoriasis onset and HLA-C*06:02 groups. Each model included exposure (biologics), effect modifier (age at onset or HLA-C*06:02 status), interaction terms and several baseline demographic, clinical and disease severity covariates. Results Final analytical cohorts included 4250 patients in the age at psoriasis onset group [2929 EOP (69%) vs. 1321 LOP (31%)] and 3094 patients in the HLA-C*06:02 status group [1603 HLA-C*06:02+ (52%) vs. 1491 HLA-C*06:02− (48%)]. There was no significant difference between EOP and LOP in drug survival associated with ineffectiveness or AEs for any biologics. However, compared with patients who were HLA-C*06:02−, patients who were HLA-C*06:02 + were less likely to discontinue ustekinumab for reasons associated with ineffectiveness (aHR 0.56, 95% CI 0.42–0.75). Conclusions HLA-C*06:02, but not age at psoriasis onset, is a predictive biomarker for biologic survival in patients with psoriasis. Findings from this large cohort provide further, important information to aid clinicians using biologic therapies to manage patients with psoriasis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects

Author

Saunders, Sean P, Goh, Christabelle SM, Brown, Sara J, Palmer, Colin NA, Porter, Rebecca M, Cole, Christian, Campbell, Linda E, Gierlinski, Marek, Barton, Geoffrey J, Schneider, Georg, Balmain, Allan, Prescott, Alan R, Weidinger, Stephan, Baurecht, Hansjörg, Kabesch, Michael, Gieger, Christian, Lee, Young-Ae, Tavendale, Roger, Mukhopadhyay, Somnath, Turner, Stephen W, Madhok, Vishnu B, Sullivan, Frank M, Relton, Caroline, Burn, John, Meggitt, Simon, Smith, Catherine H, Allen, Michael A, Barker, Jonathan NWN, Reynolds, Nick J, Cordell, Heather J, Irvine, Alan D, McLean, WH Irwin, Sandilands, Aileen, and Fallon, Padraic G

Subjects
Biomedical and Clinical Sciences, Immunology, Genetics, Eczema / Atopic Dermatitis, Aetiology, 2.1 Biological and endogenous factors, Skin, Animals, Dermatitis, Atopic, Filaggrin Proteins, Gene Expression, Genetic Predisposition to Disease, Humans, Male, Membrane Proteins, Mice, Mutation, Phenotype, Physical Chromosome Mapping, Polymorphism, Single Nucleotide, Allergy, association, atopic dermatitis, atopy, eczema, filaggrin, flaky tail, Matt, mattrin, mouse, mutation, Tmem79, AD, Atopic dermatitis, DM, Double mutant, FLG, Filaggrin, HDM, High-power field, House dust mite, MAPEG, Membrane-associated proteins in eicosanoid and glutathione metabolism, OR, Odds ratio, SNP, Single nucleotide polymorphism, TEWL, Transepidermal water loss, WT, Wild-type, hpf
Abstract

BackgroundAtopic dermatitis (AD) is a major inflammatory condition of the skin caused by inherited skin barrier deficiency, with mutations in the filaggrin gene predisposing to development of AD. Support for barrier deficiency initiating AD came from flaky tail mice, which have a frameshift mutation in Flg and also carry an unknown gene, matted, causing a matted hair phenotype.ObjectiveWe sought to identify the matted mutant gene in mice and further define whether mutations in the human gene were associated with AD.MethodsA mouse genetics approach was used to separate the matted and Flg mutations to produce congenic single-mutant strains for genetic and immunologic analysis. Next-generation sequencing was used to identify the matted gene. Five independently recruited AD case collections were analyzed to define associations between single nucleotide polymorphisms (SNPs) in the human gene and AD.ResultsThe matted phenotype in flaky tail mice is due to a mutation in the Tmem79/Matt gene, with no expression of the encoded protein mattrin in the skin of mutant mice. Matt(ft) mice spontaneously have dermatitis and atopy caused by a defective skin barrier, with mutant mice having systemic sensitization after cutaneous challenge with house dust mite allergens. Meta-analysis of 4,245 AD cases and 10,558 population-matched control subjects showed that a missense SNP, rs6684514, [corrected] in the human MATT gene has a small but significant association with AD.ConclusionIn mice mutations in Matt cause a defective skin barrier and spontaneous dermatitis and atopy. A common SNP in MATT has an association with AD in human subjects.

Published
2013

40. Dupilumab in chronic actinic dermatitis: a retrospective case series.

Author

O'Reilly, Marese, Paolino, Alexandra, Pathmarajah, Pirunthan, Ferguson, John, Smith, Catherine H, Sarkany, Robert, Dawe, Robert S, Salam, Amr, Pink, Andrew E, Fassihi, Hiva, and Ibbotson, Sally

Subjects
DUPILUMAB, SKIN inflammation, ECZEMA, LITERATURE reviews
Abstract

This article discusses the use of dupilumab in the treatment of chronic actinic dermatitis (CAD), a rare skin condition characterized by photosensitivity. The study found that while dupilumab was effective in improving dermatitis symptoms in patients with CAD and concomitant atopic dermatitis (AD), it was less effective in improving photosensitivity. The study suggests that further research is needed to evaluate the efficacy of dupilumab in CAD. [Extracted from the article]

Published
2024
Full Text
View/download PDF

41. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

Author

Tsoi, Lam C, Spain, Sarah L, Knight, Jo, Ellinghaus, Eva, Stuart, Philip E, Capon, Francesca, Ding, Jun, Li, Yanming, Tejasvi, Trilokraj, Gudjonsson, Johann E, Kang, Hyun M, Allen, Michael H, McManus, Ross, Novelli, Giuseppe, Samuelsson, Lena, Schalkwijk, Joost, Ståhle, Mona, Burden, A David, Smith, Catherine H, Cork, Michael J, Estivill, Xavier, Bowcock, Anne M, Krueger, Gerald G, Weger, Wolfgang, Worthington, Jane, Tazi-Ahnini, Rachid, Nestle, Frank O, Hayday, Adrian, Hoffmann, Per, Winkelmann, Juliane, Wijmenga, Cisca, Langford, Cordelia, Edkins, Sarah, Andrews, Robert, Blackburn, Hannah, Strange, Amy, Band, Gavin, Pearson, Richard D, Vukcevic, Damjan, Spencer, Chris CA, Deloukas, Panos, Mrowietz, Ulrich, Schreiber, Stefan, Weidinger, Stephan, Koks, Sulev, Kingo, Külli, Esko, Tonu, Metspalu, Andres, Lim, Henry W, Voorhees, John J, Weichenthal, Michael, Wichmann, H Erich, Chandran, Vinod, Rosen, Cheryl F, Rahman, Proton, Gladman, Dafna D, Griffiths, Christopher EM, Reis, Andre, Kere, Juha, Nair, Rajan P, Franke, Andre, Barker, Jonathan NWN, Abecasis, Goncalo R, Elder, James T, and Trembath, Richard C

Subjects
Genetics, Autoimmune Disease, Human Genome, Psoriasis, Aetiology, 2.1 Biological and endogenous factors, Skin, CARD Signaling Adaptor Proteins, Core Binding Factor Alpha 3 Subunit, DEAD Box Protein 58, DEAD-box RNA Helicases, GTPase-Activating Proteins, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Guanylate Cyclase, Humans, Immunity, Innate, Membrane Proteins, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Receptors, Immunologic, STAT3 Transcription Factor, T-Lymphocytes, White People, Collaborative Association Study of Psoriasis, Genetic Analysis of Psoriasis Consortium, Psoriasis Association Genetics Extension, Wellcome Trust Case Control Consortium 2, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls. We identified 15 new susceptibility loci, increasing to 36 the number associated with psoriasis in European individuals. We also identified, using conditional analyses, five independent signals within previously known loci. The newly identified loci shared with other autoimmune diseases include candidate genes with roles in regulating T-cell function (such as RUNX3, TAGAP and STAT3). Notably, they included candidate genes whose products are involved in innate host defense, including interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C) and nuclear factor (NF)-κB signaling (CARD14 and CARM1). These results portend a better understanding of shared and distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the importance of the skin in innate and acquired host defense.

Published
2012

42. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics

Author

Al-Janabi, Ali, primary, Martin, Paul, additional, Khan, Adnan R., additional, Foulkes, Amy C., additional, Smith, Catherine H., additional, Griffiths, Christopher E.M., additional, Morris, Andrew P., additional, Eyre, Steve, additional, Warren, Richard B., additional, Ahmed, Shehnaz, additional, Alabas, Oras, additional, Barker, Jonathan, additional, Becher, Gabrielle, additional, Bewley, Anthony, additional, Evans, Ian, additional, Hampton, Philip, additional, Kirby, Brian, additional, Kleyn, Elise, additional, Laws, Philip, additional, Lawson, Linda, additional, Mackenzie, Teena, additional, McElhone, Kathleen, additional, McPherson, Tess, additional, Morrison, Simon, additional, Owen, Caroline, additional, Pearson, Eleanor, additional, Rashid, Amir, additional, Reynolds, Nick, additional, Strangfeld, Anja, additional, Walton, Shernaz, additional, Yiu, Zenas, additional, Gupta, Girish, additional, Strangfeld (chair), Anja, additional, Weller, Richard, additional, Zietemann, Vera, additional, Aldoori, Nadia, additional, Ali, Mahmud, additional, Al-Rusan, Ahmed, additional, Angit, Caroline, additional, Anstey, Alex, additional, Antony, Fiona, additional, Archer, Charles, additional, August, Suzanna, additional, Balasubramaniam, Periasamy, additional, Baudry, David, additional, Baxter, Kay, additional, Bonsall, Alexandra, additional, Brown, Sara, additional, Brown, Victoria, additional, Burden, David, additional, Burova, Ekaterina, additional, Butt, Aamir, additional, Caswell, Mel, additional, Chapman, Anna, additional, Cliff, Sandeep, additional, Costache, Mihaela, additional, Darne, Sharmela, additional, DeGiovanni, Claudia, additional, Desai, Trupti, additional, Diba, Victoria, additional, Domanne, Eva, additional, Duckworth, Michael, additional, Dymond, Harvey, additional, Fahy, Caoimhe, additional, Farwer, Susanne, additional, Ferguson, Leila, additional, Gkini, Maria-Angeliki, additional, Godwin, Alison, additional, Goulding, Jon, additional, Hammonds, Fiona, additional, Haque, Shaheen, additional, Higgins, Caroline, additional, Hood, Sue, additional, Joseph, Teresa, additional, Johnson, Sarah, additional, Kalavala, Manju, additional, Khorshid, Mohsen, additional, Labinoti, Liberta, additional, Lamb, Ruth, additional, Lawson, Nicole, additional, Layton, Alison, additional, Lees, Tara, additional, Levell, Nick, additional, Lewis, Helen, additional, Lovell, Chris, additional, Lyon, Calum, additional, McAteer, Helen, additional, McBride, Sandy, additional, McCormack, Sally, additional, McKenna, Kevin, additional, Mellor, Serap, additional, Meredith, Fiona, additional, Murphy, Ruth, additional, Norris, Paul, additional, Parslew, Richard, additional, Perera, Gay, additional, Ponnambath, Nabil, additional, Popli, Urvi, additional, Powell, James, additional, Ramesh, Raakhee, additional, Ramsay, Helen, additional, Ranasinghe, Aruni, additional, Reeken, Saskia, additional, Rose, Rebecca, additional, Rotarescu, Rada, additional, Salvary, Ingrid, additional, Sands, Kathy, additional, Sinha, Tapati, additional, Schofield, Julia, additional, Shipman, Alexa, additional, Siebert, Stefan, additional, Stefanescu, Simina, additional, Sundararaj, Kavitha, additional, Taghipour, Kathy, additional, Taylor, Michelle, additional, Thomson, Michelle, additional, Topliffe, Joanne, additional, Verdolini, Roberto, additional, Wachsmuth, Rachel, additional, Wade, Martin, additional, Wahie, Shymal, additional, Walsh, Sarah, additional, Wilcox, Louise, additional, Williamson, Diane, additional, and Wright, Andrew, additional

Published
2023
Full Text
View/download PDF

46. Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case–control study.

Author

Mason, Kayleigh J, Alabas, Oras A, Dand, Nick, Warren, Richard B, Reynolds, Nick J, Barker, Jonathan N W N, Yiu, Zenas Z N, Smith, Catherine H, Griffiths, Christopher E M, and Group, the BADBIR Study

Subjects
PSORIASIS, MYOCARDIAL infarction, CASE-control method
Abstract

This document is a supplementary information section of a study conducted by the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The study aimed to investigate the factors associated with super responders (SRs) and super nonresponders (SNRs) to biologic therapies in patients with psoriasis. The study found that female sex, shorter study follow-up, higher Dermatology Life Quality Index (DLQI), high frequency of adalimumab, lower frequency of ustekinumab at registration, and higher number of comorbidities were associated with SNRs compared with SRs. The study also mentioned that genetic factors, socioeconomic status, lifestyle factors, adherence to medication, immunogenicity, microbiome, epigenetics, and serum drug levels may play a role in determining treatment response. [Extracted from the article]

Published
2024
Full Text
View/download PDF

48. AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production

Author

Mahil, Satveer K., Twelves, Sophie, Farkas, Katalin, Setta-Kaffetzi, Niovi, Burden, A. David, Gach, Joanna E., Irvine, Alan D., Képíró, László, Mockenhaupt, Maja, Oon, Hazel H., Pinner, Jason, Ranki, Annamari, Seyger, Marieke M.B., Soler-Palacin, Pere, Storan, Eoin R., Tan, Eugene S., Valeyrie-Allanore, Laurence, Young, Helen S., Trembath, Richard C., Choon, Siew-Eng, Szell, Marta, Bata-Csorgo, Zsuzsanna, Smith, Catherine H., Di Meglio, Paola, Barker, Jonathan N., and Capon, Francesca

Published
2016
Full Text
View/download PDF

50. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis

Author

Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla G S, Griffiths, Christopher E M, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Alpizar Rodriguez, Deshire, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Rajão Martins, Frederico, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, Severina, María de Los Ángeles, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas Z N, Yazdany, Jinoos, Robinson, Philip C, Smith, Catherine H, Centro de Estudos de Doenças Crónicas (CEDOC), and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
SDG 3 - Good Health and Well-being
Abstract

Funding The study received support from the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR). OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. RESULTS: Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. CONCLUSION: Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics. publishersversion published

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results